PriceTargets.com logo

Alcon - ALC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $79.80
  • Forecasted Upside: 13.13%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$70.54 As of 03/31/2023 01:00 AM ET
▼ -0.26 (-0.37%)

This chart shows the closing price for ALC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alcon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALC

Analyst Price Target is $79.80
▲ +13.13% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is $79.80, with a high forecast of $92.00 and a low forecast of $68.80. The average price target represents a 13.13% upside from the last price of $70.54.

This chart shows the closing price for ALC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in Alcon. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2023MizuhoReiterated RatingBuy$85.00N/A
3/6/2023Needham & Company LLCReiterated RatingBuy$85.00N/A
3/1/2023Societe GeneraleUpgradeSell ➝ HoldN/A
3/1/2023Robert W. BairdLower TargetNeutral$80.00 ➝ $75.00N/A
2/28/2023Needham & Company LLCReiterated RatingBuy$85.00N/A
2/3/2023Needham & Company LLCReiterated RatingBuy$85.00N/A
12/22/2022MizuhoInitiated CoverageBuy$85.00N/A
12/21/2022BTIG ResearchBoost TargetBuy$75.00 ➝ $78.00N/A
11/21/2022Credit Suisse GroupLower TargetCHF 84 ➝ CHF 80N/A
11/17/2022Societe GeneraleDowngradeHold ➝ SellN/A
11/17/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $78.00N/A
11/17/2022Wells Fargo & CompanyLower Target$90.00 ➝ $83.00N/A
11/17/2022CitigroupBoost TargetNeutral$67.00 ➝ $69.00N/A
10/17/2022BTIG ResearchLower TargetBuy$80.00 ➝ $75.00N/A
10/11/2022Morgan StanleyLower TargetEqual Weight$81.00 ➝ $71.00N/A
10/5/2022CitigroupLower Target$73.00 ➝ $67.00N/A
9/8/2022Credit Suisse GroupLower TargetCHF 96 ➝ CHF 84N/A
8/16/2022UBS GroupLower TargetCHF 88 ➝ CHF 83.80N/A
8/11/2022Societe GeneraleDowngradeBuy ➝ HoldN/A
8/11/2022Morgan StanleyLower TargetEqual Weight$83.00 ➝ $81.00N/A
8/11/2022Needham & Company LLCLower TargetBuy$87.00 ➝ $85.00N/A
6/27/2022Deutsche Bank AktiengesellschaftLower TargetCHF 85 ➝ CHF 80N/A
5/12/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ NeutralCHF 69 ➝ CHF 68.80N/A
5/12/2022StephensUpgradeEqual Weight ➝ Overweight$86.00 ➝ $92.00N/A
4/8/2022Needham & Company LLCInitiated CoverageBuy$95.00N/A
3/11/2022Bank of AmericaInitiated CoverageBuy$85.00N/A
2/18/2022JPMorgan Chase & Co.Lower TargetCHF 72.20 ➝ CHF 69N/A
2/17/2022Credit Suisse GroupBoost TargetOutperform$93.00 ➝ $96.00N/A
2/17/2022Morgan StanleyLower TargetEqual Weight$95.00 ➝ $92.00N/A
1/18/2022StephensDowngradeOverweight ➝ Equal Weight$90.00 ➝ $86.00N/A
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00N/A
11/12/2021Credit Suisse GroupBoost TargetOutperform$90.00 ➝ $93.00N/A
11/11/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
11/11/2021CitigroupBoost TargetNeutral$84.00 ➝ $87.00N/A
11/11/2021Morgan StanleyBoost TargetOverweight$92.00 ➝ $95.00N/A
9/30/2021OppenheimerInitiated CoverageMarket PerformN/A
9/13/2021Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $93.00N/A
8/27/2021Berenberg BankReiterated RatingBuyN/A
8/23/2021UBS GroupUpgradeBuyN/A
8/23/2021CitigroupBoost TargetNeutral$72.00 ➝ $84.00N/A
8/20/2021Societe GeneraleReiterated RatingHoldN/A
8/19/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
8/19/2021Credit Suisse GroupBoost TargetOutperform$86.00 ➝ $90.00N/A
8/19/2021Morgan StanleyBoost TargetOverweight$79.00 ➝ $92.00N/A
8/19/2021SVB LeerinkBoost TargetPositive ➝ Market Perform$71.00 ➝ $82.00N/A
8/19/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$83.00 ➝ $90.00N/A
8/19/2021StephensBoost TargetOverweight$79.00 ➝ $90.00N/A
8/19/2021BTIG ResearchBoost TargetBuy$80.00 ➝ $84.00N/A
7/14/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$74.00N/A
5/7/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
5/6/2021CitigroupUpgradeSell ➝ NeutralN/A
4/1/2021Berenberg BankReiterated RatingBuyN/A
3/31/2021ArgusBoost Target$72.00 ➝ $78.00N/A
3/31/2021Jefferies Financial GroupBoost TargetBuy$82.00 ➝ $85.00N/A
3/29/2021Societe GeneraleReiterated RatingHoldN/A
3/29/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00N/A
3/25/2021Jefferies Financial GroupBoost TargetBuy$82.00 ➝ $85.00N/A
3/22/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00N/A
3/5/2021Berenberg BankReiterated RatingBuyN/A
3/3/2021Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $86.00N/A
3/3/2021Morgan StanleyBoost TargetOverweight$75.00 ➝ $79.00N/A
2/26/2021Societe GeneraleUpgradeSell ➝ HoldN/A
2/25/2021Morgan StanleyReiterated RatingOverweight$75.00 ➝ $79.00N/A
2/25/2021Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $86.00N/A
1/20/2021Berenberg BankReiterated RatingBuyN/A
12/15/2020Morgan StanleyBoost TargetOverweight$73.00 ➝ $75.00N/A
11/19/2020Berenberg BankReiterated RatingBuyN/A
11/16/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
11/13/2020Credit Suisse GroupBoost TargetOutperform$71.00 ➝ $76.00N/A
11/12/2020Jefferies Financial GroupBoost TargetBuy$71.00 ➝ $78.00N/A
11/12/2020Morgan StanleyBoost TargetOverweight$66.00 ➝ $73.00N/A
11/12/2020SVB LeerinkBoost TargetMarket Perform$61.00 ➝ $67.00N/A
11/12/2020GuggenheimDowngradeBuy ➝ NeutralN/A
9/1/2020Berenberg BankReiterated RatingBuyN/A
8/27/2020Societe GeneraleDowngradeHold ➝ SellN/A
8/20/2020SVB LeerinkBoost TargetMarket Perform$57.00 ➝ $61.00N/A
8/17/2020Credit Suisse GroupReiterated RatingBuy$63.00N/A
7/6/2020KeyCorpInitiated CoverageSector WeightN/A
7/6/2020CitigroupDowngradeNeutral ➝ Sell$55.00N/A
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$68.00N/A
5/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
5/14/2020Wells Fargo & CompanyBoost TargetOverweight$58.00 ➝ $62.00N/A
5/14/2020SVB LeerinkBoost TargetMarket Perform$56.00 ➝ $57.00N/A
5/14/2020CitigroupBoost TargetNeutral$54.00 ➝ $55.00N/A
5/14/2020StephensUpgradeEqual Weight ➝ OverweightN/A
4/20/2020BTIG ResearchReiterated RatingHoldN/A
4/9/2020Wells Fargo & CompanyLower TargetOverweight$70.00 ➝ $58.00N/A
4/8/2020SVB LeerinkLower TargetMarket Perform$62.00 ➝ $56.00N/A
4/8/2020Robert W. BairdDowngradeOutperform ➝ Neutral$69.00 ➝ $58.00N/A
3/27/2020CitigroupLower TargetNeutral$63.00 ➝ $54.00N/A
3/27/2020Morgan StanleyLower TargetOverweight$70.00 ➝ $66.00N/A
3/27/2020Kepler Capital MarketsReiterated RatingSellN/A
3/26/2020ArgusUpgradeHold ➝ Buy$55.00N/A
3/24/2020Societe GeneraleUpgradeSell ➝ HoldN/A
3/23/2020StephensLower TargetEqual Weight$68.00 ➝ $50.00N/A
3/13/2020UBS GroupUpgradeNeutral ➝ BuyN/A
3/12/2020Berenberg BankReiterated RatingBuyN/A
3/11/2020SVB LeerinkLower TargetMarket Perform$68.00 ➝ $62.00N/A
3/10/2020Kepler Capital MarketsReiterated RatingSellN/A
3/6/2020Credit Suisse GroupReiterated RatingBuy$69.00N/A
3/4/2020CitigroupInitiated CoverageNeutral$63.00N/A
3/4/2020Redburn PartnersDowngradeNeutral ➝ SellN/A
2/27/2020Credit Suisse GroupBoost TargetOutperform$68.00 ➝ $72.00N/A
2/27/2020StephensBoost TargetEqual Weight$62.00 ➝ $68.00N/A
2/27/2020Kepler Capital MarketsReiterated RatingSellN/A
2/26/2020Berenberg BankUpgradeHold ➝ BuyN/A
1/8/2020ArgusInitiated CoverageHoldN/A
12/17/2019Morgan StanleyLower TargetOverweight$71.00 ➝ $70.00N/A
11/24/2019BTIG ResearchReiterated RatingHoldN/A
11/20/2019Berenberg BankReiterated RatingHoldN/A
11/11/2019Redburn PartnersUpgradeSell ➝ NeutralN/A
10/28/2019StephensInitiated CoverageEqual ➝ Equal WeightN/A
8/26/2019Credit Suisse GroupBoost TargetOutperform$68.00 ➝ $73.00N/A
8/21/2019BTIG ResearchReiterated RatingHoldN/A
8/21/2019Bank of AmericaReiterated RatingNeutral$62.00 ➝ $65.00N/A
8/16/2019Credit Suisse GroupSet TargetBuy$68.00N/A
7/16/2019Morgan StanleyBoost TargetOverweight$65.00 ➝ $71.00N/A
6/24/2019SVB LeerinkInitiated CoverageMarket Perform$62.00N/A
6/14/2019BTIG ResearchInitiated CoverageNeutral ➝ NeutralN/A
6/3/2019Credit Suisse GroupReiterated RatingOutperformN/A
5/10/2019Robert W. BairdInitiated CoverageOutperform$69.00 ➝ $68.00N/A
5/9/2019OppenheimerInitiated CoverageOutperform$69.00N/A
5/2/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$66.00N/A
4/18/2019BMO Capital MarketsInitiated CoverageMarket Perform ➝ Market PerformN/A
4/15/2019Jefferies Financial GroupInitiated CoverageBuyN/A
4/10/2019Societe GeneraleInitiated CoverageBuy ➝ BuyN/A
4/10/2019Berenberg BankInitiated CoverageHoldN/A
4/10/2019Morgan StanleyInitiated CoverageOverweight$65.00N/A
4/10/2019JPMorgan Chase & Co.Initiated CoverageNeutralN/A
4/10/2019UBS GroupInitiated CoverageNeutralN/A
4/9/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$66.00N/A
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 5 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Alcon logo
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $70.54
Low: $70.25
High: $71.30

50 Day Range

MA: $70.88
Low: $64.46
High: $77.23

52 Week Range

Now: $70.54
Low: $55.21
High: $81.97

Volume

2,263,861 shs

Average Volume

1,341,136 shs

Market Capitalization

$34.57 billion

P/E Ratio

105.28

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Alcon?

The following equities research analysts have issued research reports on Alcon in the last year: BTIG Research, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Robert W. Baird, Societe Generale, Stephens, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for ALC.

What is the current price target for Alcon?

12 Wall Street analysts have set twelve-month price targets for Alcon in the last year. Their average twelve-month price target is $79.80, suggesting a possible upside of 13.1%. Stephens has the highest price target set, predicting ALC will reach $92.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $68.80 for Alcon in the next year.
View the latest price targets for ALC.

What is the current consensus analyst rating for Alcon?

Alcon currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALC, but not buy more shares or sell existing shares.
View the latest ratings for ALC.

What other companies compete with Alcon?

Other companies that are similar to Alcon include Cooper Companies, AmerisourceBergen, ResMed, Illumina and Centene. Learn More about companies similar to Alcon.

How do I contact Alcon's investor relations team?

Alcon's physical mailing address is Rue Louis-d`Affry 6, Fribourg V8, 1701. The healthcare company's listed phone number is 418172930450 and its investor relations email address is [email protected] The official website for Alcon is www.alcon.com. Learn More about contacing Alcon investor relations.